The number of patients well suited for PET imaging with 89Zr-trastuzumab is limited, however, because the positive ratio of HER2 is at most approximately 30% in gastric cancer, as demonstrated in the present study and previous studies [27]. Here, ERBB2 is linked to gastric cancer.